% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Loureiro:300160,
      author       = {L. R. Loureiro and S. Pike and M. Wuest and C. N. Bergman
                      and K. R. JØrgensen and R. Bergmann and A. Feldmann$^*$ and
                      F. Wuest and M. Bachmann$^*$},
      title        = {{T}ackling {P}rostate {C}ancer with {T}heranostic
                      {E}5{B}9-{B}ombesin {T}arget {M}odules ({TM}s): {F}rom
                      {I}maging to {T}reatment with {U}ni{CAR} {T}-{C}ells.},
      journal      = {International journal of molecular sciences},
      volume       = {26},
      number       = {6},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2025-00646},
      pages        = {2686},
      year         = {2025},
      abstract     = {Target modules (TMs), intermediate molecules required for
                      UniCAR T-cell therapy, are promising molecules for
                      immunotheranostic approaches. In the current work, we
                      developed TMs containing a monomeric or dimeric form of the
                      antagonist bombesin peptide (BBN2) and assessed their
                      potential for diagnostic imaging using positron emission
                      tomography (PET) as well as immunotherapy in combination
                      with UniCAR T-cells to target and image GRPR expression in
                      prostate cancer. Synthesized monomeric and dimeric BBN2 TMs
                      retained binding to GRPR in vitro. Both BBN2 TMs
                      specifically activated and redirected UniCAR T-cells to
                      eradicate PC3 and LNCaP cancer cells with high efficiency
                      and in a comparable manner. UniCAR T-cells retained a
                      non-exhausted memory phenotype favorable to their
                      persistence and fitness. The 68Ga-labeled BBN2 TMs showed
                      proof-of-target towards GRPR in PC3 and LNCaP xenografts
                      with similar uptake profiles for both BBN2 TMs in dynamic
                      PET experiments. Clearance occurred exclusively through
                      renal elimination. A tremendously increased in vivo
                      metabolic stability of the BBN2 TMs was observed compared to
                      their counterparts without E5B9. Both monomeric and dimeric
                      BBN2 TMs represent novel and promising immunotheranostic
                      tools for application in prostate cancer with exceptionally
                      high in vivo metabolic stability.},
      keywords     = {Prostatic Neoplasms: diagnostic imaging / Prostatic
                      Neoplasms: therapy / Prostatic Neoplasms: metabolism /
                      Prostatic Neoplasms: pathology / Male / Humans / Animals /
                      Bombesin: chemistry / Mice / Positron-Emission Tomography:
                      methods / Cell Line, Tumor / T-Lymphocytes: immunology /
                      T-Lymphocytes: metabolism / Xenograft Model Antitumor Assays
                      / Receptors, Bombesin: metabolism / Receptors, Bombesin:
                      antagonists $\&$ inhibitors / Immunotherapy: methods /
                      Theranostic Nanomedicine: methods / PC-3 Cells / PET (Other)
                      / UniCAR T-cell therapy (Other) / bombesin (Other) /
                      prostate cancer (Other) / theranostics (Other) / Bombesin
                      (NLM Chemicals) / Receptors, Bombesin (NLM Chemicals)},
      cin          = {DD01},
      ddc          = {540},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40141329},
      doi          = {10.3390/ijms26062686},
      url          = {https://inrepo02.dkfz.de/record/300160},
}